Ratios Uncovered: Breaking Down Heron Therapeutics Inc (HRTX)’s Trailing Twelve Months Metrics

The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.

The price of Heron Therapeutics Inc (NASDAQ: HRTX) closed at $2.39 in the last session, up 1.27% from day before closing price of $2.36. In other words, the price has increased by $1.27 from its previous closing price. On the day, 1.53 million shares were traded.

Ratios:

We take a closer look at HRTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 2.29.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on June 13, 2024, initiated with a Buy rating and assigned the stock a target price of $7.

On April 23, 2024, CapitalOne started tracking the stock assigning a Overweight rating and target price of $6.

Needham reiterated its Buy rating for the stock on March 13, 2024, while the target price for the stock was revised from $4 to $5.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 2.52.

Stock Price History:

Over the past 52 weeks, HRTX has reached a high of $3.93, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is 35.30%, while the 200-Day Moving Average is calculated to be 10.42%.

Shares Statistics:

A total of 152.13M shares are outstanding, with a floating share count of 151.00M. Insiders hold about 0.87% of the company’s shares, while institutions hold 75.66% stake in the company.

Most Popular